Inder Singh
Ophthalmology · Racine, WINPI 1063430023
Payments from drug & device makers
Across 2,806 payments — averaging $1210.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$618K
- Glaukos Corporation$593K
- Bausch & Lomb Americas Inc.$409K
- Lumibird Medical Inc.$195K
- Alcon Research LLC$184K
- Alcon$182K
- plus $1.2M from 44 others
Across 29 payments — averaging $6221.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rayner Intraocular Lenses Limited$67K
- NEW World Medical,inc.$52K
- Carl Zeiss Meditec Cataract Technology Inc.$30K
- Sight Sciences, Inc.$13K
- Glaukos Corporation$11K
- Novartis$7K
- plus $1K from 2 others
What the payments were for
- Consulting fees$1,151,32646%
- Speaking & faculty fees$1,075,92743%
- Travel & lodging$164,0807%
- Food & beverage$85,7273%
- Education$7610%
- Gifts$1,6910%
- Other$8,0060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$265,202
- VYZULTA$161,206
- Tango-R SLT/YAG Combination Laser with Reflex Technology$150,192
- Hydrus Microstent$127,690
- Rocklatan$118,999
- LUMIGAN$113,623
- MIEBO$108,387
- Rhopressa$96,424
- XIIDRA$90,733
- enVista MX60 IOL$72,062
- XDEMVY$66,563
- XEN GLAUCOMA TREATMENT SYSTEM$64,746
- STELLARIS ELITE$60,200
- DEXTENZA$59,647
- Crystalens Accommodating IOL (AT-52AO)$57,884
- OMNI(R) SURGICAL SYSTEM (US)$55,675
- Trulign IOL$54,484
- iDose$46,355
- COMBIGAN$44,474
- Travoprost Intraocular Implant - iDose$43,622
How this compares
$3,395,377 in reported general payments places this provider in the 95th percentile of 337 ophthalmology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 59 | $112,736 |
| RestasisCyclosporine | 66 | $82,176 |
| XiidraLifitegrast | 56 | $67,396 |
| LumiganBimatoprost | 113 | $58,014 |
| IlevroNepafenac | 144 | $54,699 |
| MieboPerfluorohexyloctane/Pf | 66 | $51,259 |
| RocklatanNetarsudil Mesylat/Latanoprost | 110 | $47,294 |
| VyzultaLatanoprostene Bunod | 114 | $42,363 |
| ProlensaBromfenac Sodium | 62 | $23,262 |
| CombiganBrimonidine Tartrate/Timolol | 71 | $22,193 |
| RhopressaNetarsudil Mesylate | 56 | $21,216 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 74 | $18,240 |
| TobradexTobramycin/Dexamethasone | 49 | $13,221 |
| Alphagan PBrimonidine Tartrate | 29 | $8,964 |
| Lotemax SmLoteprednol Etabonate | 29 | $7,274 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $618,207 | $171,347279 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $409,108 | $161,018236 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $72,476 | $112,73659 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $88,506 | $68,510166 claims |
| NovartisIlevro | $12,715 | $54,699144 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm, Lotemax | $127,146 | $37,377110 claims |
| AlconSimbrinza | $182,027 | $18,24074 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 337 ophthalmology providers in Wisconsin.
Other ophthalmology in Racine
- Barbara BlodiMadison$2.1M
- Deepak SambharaWausau$2M
- Mihai MititeluMadison$775K
- John VukichWauwatosa$537K
- Kimberly StepienMadison$446K
- Michael AltaweelMadison$433K
- Jonathan ChangMiddleton$340K
- Eugene EldridgeKenosha$294K
- Radha SankaMount Pleasant$130K
- Swati Agarwal-SinhaGreen Bay$119K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.